Primary Sclerosing Cholangitis clinical trials at University of California Health

6 in progress, 3 open to eligible people

Showing trials for

  • Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 12 years and up

    The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

    at UC Davis

  • Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

    open to eligible people ages 18-75

    This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

    at UCSD UCSF

  • Liver Cirrhosis Network Cohort Study

    open to eligible people ages 18 years and up

    Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.

    at UCSD UCSF

  • Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

    Sorry, in progress, not accepting new patients

    This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the study drug. The trial will also study the study drug's effects on blood tests and other tests related to PSC disease activity.

    at UC Davis

  • LB-P8 in Patients With PSC

    Sorry, not yet accepting patients

    The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.

    at UC Davis

  • CM-101 in PSC Patients -The SPRING Study

    Sorry, in progress, not accepting new patients

    This study is designed to assess the safety, tolerability and activity of the anti-human CCL24 monoclonal antibody CM-101 in adult subjects with Primary Sclerosing Cholangitis (PSC). At least 68 subjects at approximately 50 sites will be randomized to receive either CM-101 at doses of 10 mg/kg or 20 mg/kg or matching placebo.

    at UC Davis

Our lead scientists for Primary Sclerosing Cholangitis research studies include .

Last updated: